Current Report Filing (8-k)
October 13 2016 - 8:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 13, 2016
bluebird bio, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-35966
|
|
13-3680878
|
|
|
|
|
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
150 Second Street
Cambridge, MA
|
|
02141
|
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code
(339) 499-9300
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item
8
.0
1
Other Events
On October 13, 2016, bluebird bio, Inc. (“bluebird
”) issued a press release announcing its research and development strategies for its gene therapy programs, including bluebird’s progress with manufacturing process improvements, planned changes to its HGB-206 clinical trial of its Lenti-Globin product candidate for the treatment of severe sickle cell disease, and regulatory updates for its Lenti-Globin product candidate for the treatment of transfusion-dependent beta-thalassemia.
The full text of bluebird’s press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
|
Description
|
|
99.1
|
|
Press release issued by bluebird bio, Inc. on October 13, 2016.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Date: October 13, 2016
|
bluebird bio, Inc.
|
|
|
By:
|
/s/ Jason F. Cole
|
|
|
|
Jason F. Cole
|
|
|
|
Chief Legal Officer
|
|
EXHIBIT
INDEX
Exhibit No.
|
|
Description
|
|
99.1
|
|
Press release issued by bluebird bio, Inc. on October 13, 2016.
|
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024